Telix Pharmaceuticals published results from the ProstACT SELECT Phase 1 study showing that TLX591-Tx, a targeted radio antibody-drug conjugate therapy for advanced metastatic prostate cancer, is safe and effective when patients are selected using 68 Ga-PSMA-PET imaging. The study demonstrated TLX591-Tx's prolonged tumor retention, low side effects on salivary glands, and a median radiographic progression-free survival of 8.8 months. These findings support ongoing Phase 3 trials aiming to improve treatment options for advanced prostate cancer patients.
Analyst firm BTIG initiated a Buy rating on Philip Morris International, with the stock trading at $188.04. They project strong Q2 earnings of $2.05 per share and revenue growth to $10.64 billion, up from last year. The company also offers an attract...
A director of City Holding Co increased their stake by purchasing 110 shares at $134.55 each, signaling confidence in the company. The stock has risen 11.27% year-to-date and is trading near its 52-week high, reflecting strong market performance. Cit...
Chubb Limited reported Q2 core operating earnings per share of $7.26, beating estimates and marking an 18.2% increase year-over-year. However, consolidated net premiums written were $14.7 billion, below the expected $15.07 billion, though key segment...
Freeport-McMoRan is forecasted to report a Q2 2026 earnings per share (EPS) of $0.60, marking an 11.1% increase year-over-year, driven by strong commodity prices and demand for copper and gold. However, revenue is expected to decline by about 14.6% t...
Stocks saw notable gains driven by specific events: Cynata Therapeutics surged over 800% due to speculative trading without known corporate news; Utz Brands jumped nearly 89% following a $14.25 per share acquisition offer now under shareholder fairne...
